ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2766

Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis

Lesley-Anne Bissell1, Elizabeth Hensor2, Sarah L. Mackie2, Agata Burska3, Jackie L. Nam2, Lukasz Kozera2, Helen I. Keen4, Edith Villeneuve2, Heike Eberl5, Helena Donica6, Philip G. Conaghan7, Jacqueline Andrews2, Paul Emery8 and Ann W. Morgan2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, Translational Research in Immune Mediated Inflammatory Diseases, the University of Leeds, Leeds, AL, United Kingdom, 4Leeds, Leeds, United Kingdom, 5Roche Molecular Diagnostics, Burgess Hill, United Kingdom, 6Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland, 7NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 8Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, infliximab and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Insulin resistance (IR), N-terminal pro-brain natriuretic peptide (NT-proBNP) and total cholesterol/high density lipoprotein cholesterol ratio (TC/HDL-C) profiles have been proposed as surrogate measures of CVD in RA, with some improving with suppression of disease activity. In early RA, few randomised controlled trials (RCTs) have compared the effects of DMARDs with TNFi on these biomarkers. A recent cohort study has linked TNFi to a reduced risk of diabetes. We aimed to determine whether TNFi had greater influence over DMARDs on homeostasis model assessment of IR (HOMA-IR), NT-proBNP and TC/HDL-C.

Methods:

The Infliximab as Induction therapy for Early rheumatoid Arthritis (IDEA) multicentre double-blind RCT recruited 112 DMARD-naïve RA patients (pts) (1987 ACR criteria; 3-12 months duration). Pts were randomised 1:1 to IFX+MTX or MTX with single-dose 250mg IV methylprednisolone (MP) as induction therapy. Treatment was blinded to week 26 then guided using a treat to target (T2T) approach. 120mg IM MP was given in both groups at weeks 6, 14 and 22 if DAS>2.4 at that visit.  A single centre conducted the CV sub-study. Fasting glucose, lipids, insulin and NT-proBNP were measured at baseline, week 26 (w26) and 78 (w78). Multiple imputation by chained equations, using predictive mean matching, created 20 datasets; linear regression analyses adjusted for baseline values. HOMA-IR (glucose*insulin/405) and NT-proBNP values were ln-transformed prior to analysis.

Results:

CV biomarker data were available for 86 pts; 7 had known CVD and were excluded from the subsequent analysis. Of the 79 pts included (age 51.6 [range 19-75], 71% female, 57% RF+ve, 72% ACPA+ve), 38 received IFX and 41 MP. Baseline clinical characteristics were similar between the two groups, including CV risk factors.  DAS44 remission rates did not differ between TNFi and DMARD groups at w26 (32% vs. 37%, p=0.956) and w78 (43% vs. 54%, p=0.593).  In both groups the three surrogate CVD markers improved on average at w26 and w78 (see Table 1). TC/HDL-C or NT-proBNP did not differ, but the TNFi group showed greater improvement in HOMA-IR at w78. Adjusting for IA/IM steroid injection dose did not alter the result.

Conclusion:

Treatment of early RA was associated with improvement in TC/HDL-C, IR and NT-proBNP.  To our knowledge this is the first double-blinded RCT to compare the change in HOMA-IR with TNFi versus non-TNFi in early DMARD-naive RA.  We determined a greater long-term improvement in HOMA-IR in those treated with TNFi; on average at w78 HOMA-IR values were around half (0.51 times) as high as those treated with MTX/IV steroid. When implementing a T2T approach, there appears to be an advantage with the use of TNFi.  Longer term follow up is underway to determine if these findings translate into reduced overt CVD.

Table 1: Changes in surrogate measures of CVD over 78 weeks

 

Baseline

Change at week 26

Change at week 78

 

MTX+IFX

n=38

MTX+IV Steroid

n=41

MTX+IFX

MTX+IV Steroid

Adjusted difference (95% CI), p-value

MTX+IFX

MTX+IV Steroid

Adjusted difference (95% CI), p-value

TC/HDL-C

(mean (SD))

5.14 (1.60)

5.71 (2.26)

-0.67

-0.96

0.11 (-0.45, 0.66),

p=0.709

-0.86

-1.01

-0.08 (-0.89, 0.73),

p=0.838

HOMA-IR

(geometric mean)*

2.17

2.54

FU/BL 0.68

FU/BL 0.69

IFX/IVS 0.87 (0.65, 1.16)

p=0.333

FU/BL 0.51

FU/BL 0.87

IFX/IVS 0.51 (0.35, 0.76)

p=0.001

NT-proBNP

(geometric mean)*

82.47

62.92

FU/BL 0.80

FU/BL 0.82

IFX/IVS 1.06 (0.77, 1.46)

p=0.708

FU/BL 0.85

FU/BL 0.88

IFX/IVS 1.06 (0.73, 1.52)

p=0.768

*it was not possible to calculate SD in original units for log-transformed variables

 


Disclosure:

L. A. Bissell,
None;

E. Hensor,
None;

S. L. Mackie,
None;

A. Burska,
None;

J. L. Nam,
None;

L. Kozera,
None;

H. I. Keen,

UCB,

5;

E. Villeneuve,

Janssen, Bristol-Myers-Squibb, Abbott, Amgen, UCB,

5;

H. Eberl,

Roche Pharmaceuticals,

3;

H. Donica,
None;

P. G. Conaghan,

Pfizer Inc, Janssen Pharmaceutica Product, L.P.,

5,

Bristol-Myers Squibb, Pfizer Inc,

8;

J. Andrews,
None;

P. Emery,

Abbvie, MSD, UCB, Pfizer, Roche, BMS,

5,

Abbvie, MSD, UCB, Pfizer, Roche, BMS,

8;

A. W. Morgan,

Merck Pharmaceuticals,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-in-insulin-resistance-greater-with-the-use-of-infliximab-following-intensive-treatment-of-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology